Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
IPO Year:
Exchange: NASDAQ
Website: altimmune.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/29/2024 | Buy → Neutral | Guggenheim | |
1/24/2024 | $13.00 | Neutral | Goldman |
3/22/2023 | $20.00 → $6.00 | Buy → Neutral | Goldman |
12/1/2022 | $20.00 | Buy | Goldman |
12/29/2021 | $30.00 | Buy | Jefferies |
6/30/2021 | $41.00 → $21.00 | Buy | B. Riley Securities |
6/30/2021 | $53.00 → $31.00 | Market Outperform | JMP Securities |
6/30/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
DEF 14A - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
10-Q - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
10-Q - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
S-8 - Altimmune, Inc. (0001326190) (Filer)
10-K - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
3 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Details for the presentations are as follows: Title:Pemvidutide preserves lean body mass during weight loss in pati
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will b
Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment LFC changes were accompanied by significant improvements in body weight and non-invasive markers of liver inflammation Pemvidutide is currently being evaluated in the Phase 2b IMPACT trial in subjects with metabolic dysfunction-associated steatohepatitis (MASH), with data readout expected in Q1 2025 GAITHERSBURG, Md., July 25, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the data from its 12-week clinical trial of pemviduti
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation pepti
GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Company's Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024. "We are all shocked and saddened by Rich's passing. On behalf of everyone at Altimmune, I extend our heartfelt condolences to his family during this difficult time," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Rich was not only a brilliant and dedicated leader, but a close friend who brought a sense of wit and joy to our workplace that will be dearly missed by all who had the privilege of working wit
GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association's (ADA) 84th Scientific Sessions. "We're pleased with the data presented at ADA that highlight the impressive lean mass preservation achieved with pemvidutide, with only 21.9% of weight loss attributable to lean mass," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "The preserv
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association's (ADA) 84th Scientific Sessions. "Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of patients with obesity," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "These data add to the differentiated profile of pemvidutide and reinforce its pot
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association's (ADA) Scientific Sessions. Details on the fireside chat are as follows: Title:Piper Sandler Virtual Obesity Investor Day Presenters:Vipin Garg, Ph.D., Chief Executive OfficerScott Roberts, Ph.D., Chief Scientific Officer Date/Time:Wednesday, June 26, 2024 at 9:30 a.m. EDT The session will be webcast and can be
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) computational model, pemvidutide's GLP-1/glucagon dual agonism could have additive effects on MASH resolution and fibrosis improvement compared with GLP-1 alone Lipidomic profiling reinforces the disease modifying potential of pemvidutide on MASH and MASH-associated co-morbidities, including cardiovascular disease Pemvidutide is currently being evaluated in the ongoing Phase 2b IMPACT
https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company’s chief financial officer. What To Know: Eisenstadt’s sudden death has deeply saddened Altimmune, with CEO Vipin K. Garg highlighting his contributions and personal qualities that endeared him to colleagues. In response to Eisenstadt’s passing, Altimmune’s finance and accounting functions are temporarily being managed by the existing team while the company initiates a search for his replacement. This transition period aims to maintain stability amid the loss of a key executive. Altimmune is a clinical-stage biopharmaceutical firm specia
B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.
Altimmune Inc (NASDAQ:ALT) shares are trading higher Monday after the company announced data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide. What Happened: Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes Association’s 84th Scientific Sessions. Pemvidutide is the clinical-stage biopharmaceutical company’s GLP-1/glucagon dual receptor agonist candidate. The trial enrolled 391 subjects with obesity, or overweight with at least one co-morbidity and without diabetes. At week 48, subjects receiving pemvidutide achieved mean wei
ALNY: 14% | Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Phase 3 study of vutrisiran and that it met the primary endpoints and demonstrated statistically significant improvements across all secondary endpoints. ALT: 20% | Altimmune shares are trading higher after the company announced that it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association's 84th Scientific Sessions. RGLS: 41% | Regulus Therapeutics shares are trading higher after the company announced topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) shares rose sharply in today's pre-market trading after the company inked a definitive agreement to acquire Coyote Logistics from United Parcel Service, Inc. (NYSE:UPS) for $1.025 billion in cash. As per the terms, the transaction disclosed on Sunday will be financed through a combination of equity and debt, including a $300 million equity investment from MFN Partners and a $250 million equity investment from Orbis Investments, both significant shareholders of RXO. RXO shares jumped 13.3% to $22.90 in pre-market trading. Here are some big s
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
SC 13G/A - Altimmune, Inc. (0001326190) (Subject)
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will b
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. "As the obesity therapeutics space evolves, increasing attention is being placed on agents that are able to drive weight loss while addressing the qua
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be availa
Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results showed a direct anti-fibrotic effect of pemvidutide in anon-steatotic model of liver fibrosis Cash, cash equivalents and short-term investments of $198.0 million at December 31, 2023 Webcast to be held today, March 27, 2024, at 8:30 am ET GAITHERSBURG, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biophar
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call,
Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatmentOver 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks Robust reductions in BMI and serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate Altimmune to host conference call tomorrow at 8:30 am EST GAITHERSBURG, Md., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company (the "Company"), today announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. The trial enro
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Pemvidutide granted Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, November 7, 2023, at 8:30 am EST GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update. "The next few months will be important as we receive the data from our 48-week MOMENTUM trial of pemvidutide in
GAITHERSBURG, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 7 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a rep
Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 Commenced enrollment in IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) Top-line results from the Phase 2 trial of HepTcell™ in chronic hepatitis B (CHB) expected Q1 2024 Webcast to be held today, August 10, 2023, at 8:30 am EDT GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended June 30, 2023, and provided a business update. "We are pleased to have commenced enrollment in our IMPACT Phase 2b biopsy-driven trial of pemvidutide in NASH," said
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Will Brown as Chief Financial Officer and member of the company's Executive Committee, effective January 1, 2022. "We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "This is an exciting time for ObsEva on the heels of the
Guggenheim downgraded Altimmune from Buy to Neutral
Goldman initiated coverage of Altimmune with a rating of Neutral and set a new price target of $13.00
Goldman downgraded Altimmune from Buy to Neutral and set a new price target of $6.00 from $20.00 previously
Goldman initiated coverage of Altimmune with a rating of Buy and set a new price target of $20.00
Jefferies resumed coverage of Altimmune with a rating of Buy and set a new price target of $30.00
B. Riley Securities reiterated coverage of Altimmune with a rating of Buy and set a new price target of $21.00 from $41.00 previously
JMP Securities reiterated coverage of Altimmune with a rating of Market Outperform and set a new price target of $31.00 from $53.00 previously
HC Wainwright & Co. reiterated coverage of Altimmune with a rating of Buy and set a new price target of $25.00 from $35.00 previously
JMP Securities reiterated coverage of Altimmune with a rating of Market Outperform and set a new price target of $53.00 from $45.00 previously
HC Wainwright & Co. initiated coverage of Altimmune with a rating of Buy and set a new price target of $35.00